Video

Vibeke Strand, MD: There are Options for Treating Psoriatic Arthritis

Author(s):

Vibeke Strand, MD, shares that based on her data, secukinumab is an effective option for treating patients with psoriatic arthritis.

Vibeke Strand, MD, MACR, FACP, Division of Immunology and Rheumatology, Stanford University, conducted a study on the effect of secukinumab in patients with active psoriatic arthritis (PsA). In an interview with HCPLive®, she explained that even treatment-resistant patients showed significant improvement.

The Phase 3 study included patients who were naive to tumor necrosis factor (TNF) inhibitor, as well as patients who were TNF-inadequate or TNF-incomplete responders.

Strand said that this extensive dataset gives a comprehensive overview of secukinumab, which is just one of the various treatment options that healthcare providers have to treat their patients with psoriatic arthritis.

"So, part of this analysis was to really help healthcare providers to understand what this particular IL-17 can do, and where they might want to fit it into their treatment armamentarium," Strand said. "So, in other words, it's never too late to use it, but you can also use it early. And you'll see extensively more benefit in patients with shorter disease duration and less treatment failures."

Related Videos
Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
© 2025 MJH Life Sciences

All rights reserved.